230 related articles for article (PubMed ID: 36030360)
1. Cost-effectiveness of direct surgery versus preoperative octreotide therapy for growth-hormone secreting pituitary adenomas.
Caulley L; Krijkamp E; Doyle MA; Thavorn K; Alkherayf F; Sahlollbey N; Dong SX; Quinn J; Johnson-Obaseki S; Schramm D; Kilty SJ; Hunink MGM
Pituitary; 2022 Dec; 25(6):868-881. PubMed ID: 36030360
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of postoperative imaging surveillance strategies for nonfunctional pituitary adenomas after resection with curative intent.
Caulley L; Dijk SW; Krijkamp E; Dong SX; Alkherayf F; Amrani L; Doyle MA; Eid A; Johnson-Obaseki S; Khoury M; Malcolm J; Mavedatnia D; Sahlollbey N; Schramm D; Whelan J; Thavorn K; Kilty S; Hunink MGM
J Neurosurg; 2023 Nov; 139(5):1207-1215. PubMed ID: 37922550
[TBL] [Abstract][Full Text] [Related]
3. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Radiation Therapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma.
Rodin D; Caulley L; Burger E; Kim J; Johnson-Obaseki S; Palma D; Louie AV; Hansen A; O'Sullivan B
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):709-717. PubMed ID: 28244405
[TBL] [Abstract][Full Text] [Related]
5. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre.
Abe T; Lüdecke DK
Eur J Endocrinol; 2001 Aug; 145(2):137-45. PubMed ID: 11454508
[TBL] [Abstract][Full Text] [Related]
6. Preoperative prediction of granulation pattern subtypes in GH-secreting pituitary adenomas.
Heng L; Liu X; Jia D; Guo W; Zhang S; Gao G; Gong L; Qu Y
Clin Endocrinol (Oxf); 2021 Jul; 95(1):134-142. PubMed ID: 33738801
[TBL] [Abstract][Full Text] [Related]
7. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.
Fukuhara N; Horiguchi K; Nishioka H; Suzuki H; Takeshita A; Takeuchi Y; Inoshita N; Yamada S
Endocr J; 2015; 62(1):21-7. PubMed ID: 25273395
[TBL] [Abstract][Full Text] [Related]
8. Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide.
Orme SM; Lamb JT; Nelson M; Belchetz PE
Postgrad Med J; 1991 May; 67(787):466-8. PubMed ID: 1852668
[TBL] [Abstract][Full Text] [Related]
9. Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.
Yin J; Su CB; Xu ZQ; Yang Y; Ma WB; Tao W; Yang Z; Xia XW
Chin Med Sci J; 2005 Mar; 20(1):23-6. PubMed ID: 15844307
[TBL] [Abstract][Full Text] [Related]
10. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
11. The effect of preoperative short-term octreotide treatment to surgery in thyrotropin-secreting pituitary adenomas: a retrospective cohort study.
Zhao R; Fan K; Wan W
BMC Endocr Disord; 2023 Aug; 23(1):176. PubMed ID: 37587420
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the long-acting octreotide formulation in patients with thyroid-stimulating hormone-secreting pituitary adenomas after incomplete surgery and octreotide treatment failure.
Zhang CF; Liang D; Zhong LY
Chin Med J (Engl); 2012 Aug; 125(15):2758-63. PubMed ID: 22931988
[TBL] [Abstract][Full Text] [Related]
13. The role of octreotide (Sandostatin) in non-growth hormone-, non-thyroid-stimulating hormone-, and non-prolactin-secreting adenomas.
Warnet A
Metabolism; 1992 Sep; 41(9 Suppl 2):59-61. PubMed ID: 1325596
[TBL] [Abstract][Full Text] [Related]
14. Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study.
Kristof RA; Stoffel-Wagner B; Klingmüller D; Schramm J
Acta Neurochir (Wien); 1999; 141(4):399-405. PubMed ID: 10352750
[TBL] [Abstract][Full Text] [Related]
15. Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage.
Oshino S; Saitoh Y; Kasayama S; Arita N; Ohnishi T; Kohara H; Izumoto S; Yoshimine T
Endocr J; 2006 Feb; 53(1):125-32. PubMed ID: 16543682
[TBL] [Abstract][Full Text] [Related]
16. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients.
Chanson P; Weintraub BD; Harris AG
Ann Intern Med; 1993 Aug; 119(3):236-40. PubMed ID: 8323093
[TBL] [Abstract][Full Text] [Related]
17. 111In-octreotide scintigraphy in pituitary adenomas.
Tofani A; Cucchi R; Pompili A; Carapella C; Crecco M; Mottolese M; Maini CL
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):94-7. PubMed ID: 9002760
[TBL] [Abstract][Full Text] [Related]
18. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
19. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR.
Lundin P; Edén Engström B; Karlsson FA; Burman P
AJNR Am J Neuroradiol; 1997 Apr; 18(4):765-72. PubMed ID: 9127047
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
